Leadership & Pay ·
GeoVax terminates CEO David Dodd for cause amid potential dispute over severance
GOVXGeoVax Labs, Inc.
The Board of Directors terminated President and CEO David Dodd effective November 5, 2026, citing his refusal to comply with board directives. The company classified the termination as for 'Cause,' meaning it does not intend to pay the three-times-salary-and-bonus severance or accelerate stock option vesting required under his employment agreement if terminated without cause. Dodd remains a director and chairman of the board but may dispute the classification, potentially triggering significant cash payouts and legal costs. GeoVax Labs develops immuno-oncology products and preventative vaccines.